Boston Children's Hospital
- Country
- πΊπΈUnited States
- Ownership
- -
- Established
- 1869-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
576
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (365 trials with phase data)β’ Click on a phase to view related trials
Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations
- Conditions
- Cowden's DiseaseCowden's SyndromeLhermitte-Duclos DiseaseCerebellum Dysplastic GangliocytomaBannayan Zonana SyndromeMyhre Riley Smith SyndromeRiley Smith SyndromePTEN Hamartoma Tumor SyndromeBannayan Riley Ruvalcaba Syndrome
- Interventions
- Drug: Everolimus blinded oral capsulesDrug: Placebo
- First Posted Date
- 2025-10-20
- Last Posted Date
- 2025-10-20
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT07218575
Dietary Intervention Using a Gluten-free App to Improve Tracking, Adherence, and Learning(DIGITAL) Study
- Conditions
- Celiac Disease in Children
- First Posted Date
- 2025-09-25
- Last Posted Date
- 2025-09-29
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT07192874
Assessment of Microvascular Circulation in the Pediatric Cardiac Surgery Patient
- Conditions
- Tetrology of Fallot
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT07184476
Exercise as Medicine for Pediatric Chronic Pain
- Conditions
- Chronic PainAdolescentChild
- First Posted Date
- 2025-09-19
- Last Posted Date
- 2025-09-19
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 66
- Registration Number
- NCT07182006
- Locations
- πΊπΈ
Boston Children's Hospital at 2 Brookline Place, Brookline, Massachusetts, United States
Genetics of Neonatal Encephalopathy and Related Disorders
- Conditions
- Neonatal EncephalopathyHypoxic Ischaemic Encephalopathy (HIE)
- First Posted Date
- 2025-09-10
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- Boston Children's Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT07165938
- Locations
- πΊπΈ
Boston Children's Hospital, Boston, Massachusetts, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 116
- Next
News
Ovid Therapeutics' OV329 Shows 53% GABA Inhibition in Phase 1 Trial for Drug-Resistant Epilepsy
Ovid Therapeutics announced positive Phase 1 results for OV329, a next-generation GABA-aminotransferase inhibitor, showing 53% inhibition of GABA-AT at 5 mg dose with statistical significance (p=0.0001).
Apertura Gene Therapy Licenses Blood-Brain Barrier-Penetrant AAV Capsid to Multiple Partners for CNS Treatments
Apertura Gene Therapy has licensed its novel TfR1 CapX capsid technology to Galibra Neuroscience and Emugen Therapeutics for central nervous system gene therapy programs.
Insulin Access Disparities Persist Despite Cost Stabilization, Study Reveals Long-Term Health System Burden
A comprehensive analysis of insulin out-of-pocket costs and usage patterns from 2008-2021 reveals persistent disparities in insulin access between higher-income and lower-income patients with diabetes.
Dana-Farber, Boston Children's Hospital, and Broad Clinical Labs Launch BrightSeq Initiative for Pediatric Cancer Genomics
Dana-Farber Cancer Institute, Boston Children's Hospital, and Broad Clinical Labs have formed BrightSeq, a collaborative initiative to develop clinical molecular testing assays specifically for pediatric cancers.
First Commercial Brain Gene Therapy Treatments Delivered in US Using ClearPoint Neuro's SmartFlow Cannula
The first commercial gene therapy treatments ever delivered directly to the brain in the United States have been successfully performed using ClearPoint Neuro's SmartFlow Neuro Cannula to administer KEBILIDI for AADC deficiency.
NS Pharma and Boston Children's Hospital Form Strategic Alliance to Advance Rare Disease Therapies
NS Pharma's parent company Nippon Shinyaku has finalized a strategic partnership with Boston Children's Hospital to develop innovative therapies for rare diseases.
Psilocybin Clinical Trial Targets Treatment-Resistant IBS in Groundbreaking Gastroenterology Study
Dr. Erin E. Mauney at Massachusetts General Hospital is conducting the first clinical trial examining psilocybin's effects on treatment-resistant irritable bowel syndrome (IBS).
Dupilumab Reduces Asthma Exacerbations in Children Regardless of Disease Duration
Children with uncontrolled moderate to severe asthma experienced significantly fewer exacerbations when treated with dupilumab compared to placebo, regardless of how long they had been living with the disease.
FDA Clears BlackfinBio's Novel Gene Therapy Trial for Rare Childhood Neurological Disease SPG47
The FDA has cleared BlackfinBio's IND application to begin a Phase 1/2 clinical trial of BFB-101, a gene therapy designed to treat Hereditary Spastic Paraplegia Type 47 (SPG47), a rare neurological disorder with no existing treatments.
FDA Expands Luminopia's Digital Therapeutic Approval for Amblyopia Treatment to Children Aged 8-12
Luminopia's VR-based digital therapeutic for amblyopia has received FDA clearance for children aged 8-12 years, expanding from its previous 4-7 year age indication based on robust real-world evidence.